This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
billion and $812 million in 2028. Competition in an increasingly heated market. Vaxcyte’s recent clinical success brings further competition into a sector, which is becoming increasingly heated. The post Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine appeared first on Pharmaceutical Technology.
million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. The potential increase in industry competition could also spell trouble for some. Now, the demand for such equipment is on track to grow exponentially.
These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition. Starting in 2019, the US market was valued at $4.5
“Programmes available to industries are a little bit and diverse and convoluted, and Catapult is [hoping] to look at ways [to] simplify the process and provide access easy access to various skills trainings programmes.” For example, these are apprenticeship and graduate schemes as well as career converters, Evans explained.
Cons: Highly competitive with new options continually emerging. Training and/or certifications may be required. That being said, the clinical laboratory market is expected to see growth of nearly 40% by 2028. Pros: A growing market means a good chance for long-term success with each client. Opportunities: Liquid Amnion.
million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. The potential increase in industry competition could also spell trouble for some. Now, the demand for such equipment is on track to grow exponentially.
billion by 2028. That means competition is fierce, especially in high-growth locations. Maybe they need to receive more training so that they can implement your team’s sales strategy effectively. The industry grew by 2.7% annually from 2015 to 2020 and is expected to reach $32.14 increase from last year.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content